Dapagliflozin to help the heart heal after a heart attack
Part of Heart & circulation clinical trials.
This trial tests whether dapagliflozin (a diabetes medicine also used for heart protection) can reduce harmful heart “remodeling” after an acute heart attack. It may help your heart function and structure recover over the following 6 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- Your heart attack was recent, and you had either STEMI or very high-risk NSTEMI, and you finished PCI or angiography.
- Your heart pumping function is reduced (left ventricular ejection fraction of 45% or less).
- Your kidney function is adequate (eGFR 25 or higher) and your blood pressure is not too low before starting (systolic over 100 and/or diastolic over 70).
- You do not have an ongoing atrial fibrillation rhythm, and the study heart scans (echocardiogram) can be done clearly with your device situation.
- You can sign consent and agree to be followed for 6 months, and you are covered by the French health system (AME not allowed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the drug dapagliflozin (a medicine that helps protect the heart and kidneys) can improve recovery in patients who needed a breathing machine or blood pressure support in the ICU. If you qualify, you would take the drug after leaving the ICU to see if it lowers the risk of heart or kidney problems.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.
This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.
This study tests whether a diabetes drug called dapagliflozin (Farxiga) can help protect your kidney function and heart health after a kidney transplant. It's for people who have had a transplant for at least a year and have diabetes or post-transplant diabetes.
Hear when a new AMI trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.